{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:49:41Z","timestamp":1791856181602,"version":"4.3.4"},"reference-count":90,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research University Individual grant, Universiti Sains Malaysia","award":["1001\/CIPPM\/ 8012305"],"award-info":[{"award-number":["1001\/CIPPM\/ 8012305"]}]},{"name":"Malaysian Ministry of Education, Higher Institution Centre of Excellence (HICoE) Grant","award":["311\/CIPPM\/4401005"],"award-info":[{"award-number":["311\/CIPPM\/4401005"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Approximately 100\u2013400 million people from more than 100 countries in the tropical and subtropical world are affected by dengue infections. Recent scientific breakthroughs have brought new insights into novel strategies for the production of dengue antivirals and vaccines. The search for specific dengue inhibitors is expanding, and the mechanisms for evaluating the efficacy of novel drugs are currently established, allowing for expedited translation into human trials. Furthermore, in the aftermath of the only FDA-approved vaccine, Dengvaxia, a safer and more effective dengue vaccine candidate is making its way through the clinical trials. Until an effective antiviral therapy and licensed vaccine are available, disease monitoring and vector population control will be the mainstays of dengue prevention. In this article, we highlighted recent advances made in the perspectives of efforts made recently, in dengue vaccine development and dengue antiviral drug.<\/jats:p>","DOI":"10.3390\/molecules26226768","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T12:46:23Z","timestamp":1636461983000},"page":"6768","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Updates on Dengue Vaccine and Antiviral: Where Are We Heading?"],"prefix":"10.3390","volume":"26","author":[{"given":"Harun","family":"Norshidah","sequence":"first","affiliation":[{"name":"Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Gelugor 11800, Penang, Malaysia"},{"name":"Faculty of Pharmacy and Health Sciences, Universiti Kuala Lumpur-Royal College of Medicine Perak, Ipoh 30450, Perak, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramachandran","family":"Vignesh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universiti Kuala Lumpur-Royal College of Medicine Perak, Ipoh 30450, Perak, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngit Shin","family":"Lai","sequence":"additional","affiliation":[{"name":"Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Gelugor 11800, Penang, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e2093","DOI":"10.1002\/rmv.2093","article-title":"Prevalence and burden of dengue infection in Europe: A systematic review and meta-analysis","volume":"30","author":"Ahmed","year":"2020","journal-title":"Rev. Med. Virol."},{"key":"ref_2","unstructured":"World Health Organization (2021, January 11). Dengue and Severe Dengue. Dengue Fact Sheet. Available online: http:\/\/www.searo.who.int\/entity\/vector_borne_tropical_diseases\/data\/data_factsheet\/en\/."},{"key":"ref_3","unstructured":"EDCD (Epidemiology and Disease Control Division) (2021, October 22). Updates on Dengue Fever, Available online: http:\/\/edcd.gov.np\/resources\/download\/dengue-update-as-of-1st-ashoj-2076."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Hossain, M.S., Siddiqee, M.H., Siddiqi, U.R., Raheem, E., Akter, R., and Hu, W. (2020). Dengue in a crowded megacity: Lessons learnt from 2019 outbreak in Dhaka, Bangladesh. PLoS Negl. Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0008349"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijid.2021.04.010","article-title":"Co-circulation of three dengue virus serotypes led to a severe dengue outbreak in Xishuangbanna, a border area of China, Myanmar, and Laos, in 2019","volume":"107","author":"Zhang","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","article-title":"The current and future global distribution and population at risk of dengue","volume":"4","author":"Messina","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nrmicro3030","article-title":"Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis","volume":"11","author":"Abraham","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Murugesan, A., and Manoharan, M. (2020). Dengue Virus. Emerging and Reemerging Viral Pathogens, Elsevier.","DOI":"10.1016\/B978-0-12-819400-3.00016-8"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e5068","DOI":"10.7717\/peerj.5068","article-title":"Using bioinformatics tools for the discovery of Dengue RNA-dependent RNA polymerase inhibitors","volume":"6","author":"Nncube","year":"2018","journal-title":"PeerJ"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0065-3527(03)59009-1","article-title":"Microevolution and virulence of dengue viruses","volume":"59","year":"2003","journal-title":"Adv. Virus Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3389\/fmicb.2016.00875","article-title":"DGV: Dengue Genographic Viewer","volume":"7","author":"Yamashita","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_13","first-page":"355","article-title":"Persistence of symptoms in dengue patients: A clinical cohort study","volume":"114","author":"Undurraga","year":"2021","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.13005\/bbra\/2854","article-title":"Dengue Vector Control: A Review for Wolbachia-Based Strategies","volume":"17","author":"Alkuriji","year":"2020","journal-title":"Biosci. Biotechnol. Res. Asia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-66212-5","article-title":"Knowledge, attitude and practice on dengue prevention and dengue seroprevalence in a dengue hotspot in Malaysia: A cross-sectional study","volume":"10","author":"Selvarajoo","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wellekens, K., Betrains, A., De Munter, P., and Peetermans, W. (2020). Dengue: Current state one year before WHO 2010\u20132020 goals. Acta Clin. Belgica Int. J. Clin. Lab. Med., 1\u20139.","DOI":"10.1080\/17843286.2020.1837576"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Whitehead, S.S., Durbin, A.P., Pierce, K.K., Elwood, D., McElvany, B.D., Fraser, E.A., Carmolli, M.P., Tibery, C.M., Hynes, N.A., and Jo, M. (2017). In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005584"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults","volume":"212","author":"Kirkpatrick","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/infdis\/jiv762","article-title":"Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study","volume":"213","author":"Sirivichayakul","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4269\/ajtmh.2012.12-0361","article-title":"A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults","volume":"88","author":"Thomas","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4269\/ajtmh.14-0625","article-title":"A phase II, randomized, safety and immunogenicity trial of a re-derived, live-attenuated dengue virus vaccine in healthy children and adults living in puerto rico","volume":"93","author":"Bauer","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4269\/ajtmh.16-0634","article-title":"Phase 1 randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the United States","volume":"96","author":"Schmidt","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4269\/ajtmh.19-0461","article-title":"Safety and immunogenicity of different formulations of a tetravalent dengue purified inactivated vaccine in healthy adults from Puerto Rico: Final results after 3 years of follow-up from a randomized, placebo-controlled phase I study","volume":"102","author":"Diaz","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1016\/j.vaccine.2011.07.021","article-title":"The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease","volume":"29","author":"Coller","year":"2011","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1080\/21645515.2018.1546523","article-title":"Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: Results of a Phase I randomized clinical trial in flavivirus-na\u00efve adults","volume":"15","author":"Manoff","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.vaccine.2010.11.050","article-title":"Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial","volume":"29","author":"Beckett","year":"2011","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1016\/S0264-410X(00)00105-5","article-title":"A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys","volume":"18","author":"Kochel","year":"2000","journal-title":"Vaccine"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21384-0","article-title":"A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans","volume":"12","author":"Nivarthi","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"251513552110158","DOI":"10.1177\/25151355211015839","article-title":"Dengvaxia: The world\u2019s first vaccine for prevention of secondary dengue","volume":"9","author":"Tully","year":"2021","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_33","unstructured":"FDA (2021, October 26). Dengvaxia FDA 2019, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/dengvaxia."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrmicro.2015.2","article-title":"Dengue vaccine: Hypotheses to understand CYD-TDV-induced protection","volume":"14","author":"Guy","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"572681","DOI":"10.3389\/fcimb.2020.572681","article-title":"Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine","volume":"10","author":"Shukla","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1016\/j.vaccine.2020.06.079","article-title":"Ethics of a partially effective dengue vaccine: Lessons from the Philippines","volume":"38","author":"Halstead","year":"2020","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1586\/14760584.2016.1115727","article-title":"Development of TV003\/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; What makes this vaccine different from the Sanofi-Pasteur CYDTM vaccine?","volume":"15","author":"Whitehead","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"White, L.J., Young, E.F., Stoops, M.J., Henein, S.R., Adams, E.C., Baric, R.S., and de Silva, A.M. (2021). Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (Tak-003). PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009258"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/imm.12681","article-title":"CD4+ and CD8+ T-cell immunity to Dengue\u2014Lessons for the study of Zika virus","volume":"150","author":"Rivino","year":"2017","journal-title":"Immunology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4269\/ajtmh.13-0452","article-title":"Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: A randomized trial","volume":"91","author":"Watanaveeradej","year":"2014","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/infdis\/174.6.1176","article-title":"Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: Immunogenicity and protection in mice and rhesus monkeys","volume":"174","author":"Putnak","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_42","first-page":"178","article-title":"Dengue vaccine: Global development update","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.3389\/fimmu.2018.01919","article-title":"Recent Developments in Recombinant Protein\u2013Based Dengue Vaccines","volume":"9","author":"Tripathi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cben.201600002","article-title":"Production and purification of recombinant proteins from Escherichia coli","volume":"3","author":"Tripathi","year":"2016","journal-title":"ChemBioEng Rev."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Azevedo, A.S., Yamamura, A.M.Y., Freire, M.S., Trindade, G.F., Bonaldo, M., Galler, R., and Alves, A.M.B. (2011). DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020528"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/j.vaccine.2011.01.077","article-title":"Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys","volume":"29","author":"Maves","year":"2011","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3389\/fimmu.2020.01055","article-title":"Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity","volume":"11","author":"Izmirly","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.antiviral.2008.08.004","article-title":"Molecular targets for flavivirus drug discovery","volume":"81","author":"Sampath","year":"2009","journal-title":"Antivir. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrmicro.2017.170","article-title":"Rewiring cellular networks by members of the Flaviviridae family","volume":"16","author":"Neufeldt","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/cbdd.12576","article-title":"A Peptide Inhibitor Derived from the Conserved Ectodomain Region of DENV Membrane (M) Protein with Activity Against Dengue Virus Infection","volume":"86","author":"Panya","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10867-018-9515-6","article-title":"Dynamics and binding interactions of peptide inhibitors of dengue virus entry","volume":"45","author":"Zain","year":"2019","journal-title":"J. Biol. Phys."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"104636","DOI":"10.1016\/j.antiviral.2019.104636","article-title":"A novel flavivirus entry inhibitor, BP34610, discovered through high-throughput screening with dengue reporter viruses","volume":"172","author":"Yang","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1021\/cb500640t","article-title":"Understanding Dengue Virus Capsid Protein Disordered N-Terminus and pep14-23-Based Inhibition","volume":"10","author":"Faustino","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2018.04.019","article-title":"Characterization and structure-activity relationship analysis of a class of antiviral compounds that directly bind dengue virus capsid protein and are incorporated into virions","volume":"155","author":"Smith","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1039\/C5RA14469H","article-title":"Reaching beyond HIV\/HCV: Nelfinavir as a potential starting point for broad-spectrum protease inhibitors against dengue and chikungunya virus","volume":"5","author":"Bhakat","year":"2015","journal-title":"RSC Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12985-015-0248-x","article-title":"A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture","volume":"12","author":"Raut","year":"2015","journal-title":"Virol. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/aps.2015.56","article-title":"Policresulen, a novel NS2B\/NS3 protease inhibitor, effectively inhibits the replication of DENV2 virus in BHK-21 cells","volume":"36","author":"Wu","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7733","DOI":"10.1021\/acs.jmedchem.5b00612","article-title":"Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors","volume":"58","author":"Weigel","year":"2015","journal-title":"J. Med. Chem"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"9354","DOI":"10.1021\/acs.jmedchem.5b01441","article-title":"Discovery of Nanomolar Dengue and West Nile Virus Protease Inhibitors Containing a 4-Benzyloxyphenylglycine Residue","volume":"58","author":"Behnam","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/cbdd.12500","article-title":"Structure-guided Discovery of a Novel Non-peptide Inhibitor of Dengue Virus NS2B\u2013NS3 Protease","volume":"86","author":"Li","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.antiviral.2016.08.014","article-title":"High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease","volume":"134","author":"Balasubramanian","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e3196","DOI":"10.1002\/psc.3196","article-title":"Carnosine exhibits significant antiviral activity against Dengue and Zika virus","volume":"25","author":"Rothan","year":"2019","journal-title":"J. Pept. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e2838","DOI":"10.1002\/jmr.2838","article-title":"Structure-guided screening of chemical database to identify NS3-NS2B inhibitors for effective therapeutic application in dengue infection","volume":"33","author":"Bhowmick","year":"2020","journal-title":"J. Mol. Recognit."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"103567","DOI":"10.1016\/j.bioorg.2020.103567","article-title":"Synthesis and evaluation of novel S-benzyl-and S-alkylphthalimide-oxadiazole-benzenesulfonamide hybrids as inhibitors of dengue virus protease","volume":"96","author":"Hamdani","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_65","first-page":"264","article-title":"Molecular docking and pharmacokinetics study for selected leaf phytochemicals from Carica papaya Linn. against dengue virus protein, NS2B\/NS3 protease","volume":"124","author":"Ghosh","year":"2019","journal-title":"World Sci. News"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1080\/07391102.2019.1678523","article-title":"The identification of active compounds in Ganoderma lucidum var. antler extract inhibiting dengue virus serine protease and its computational studies","volume":"38","author":"Lim","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_67","first-page":"355","article-title":"Exploration of Carica papaya bioactive compounds as potential inhibitors of dengue NS2B, NS3 and NS5 protease","volume":"33","author":"Farooq","year":"2020","journal-title":"Pak. J. Pharm. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.antiviral.2018.12.002","article-title":"Inhibition of dengue virus by curcuminoids","volume":"162","author":"Balasubramanian","year":"2019","journal-title":"Antivir. Res"},{"key":"ref_69","first-page":"1934578X19861014","article-title":"Chemical Constituents From Endiandra kingiana (Lauraceae) as Potential Inhibitors for Dengue Type 2 NS2B\/NS3 Serine Protease and its Molecular Docking","volume":"14","author":"Sulaiman","year":"2019","journal-title":"Nat. Prod. Commun."},{"key":"ref_70","first-page":"357","article-title":"Dengue protease inhibition activity of selected Malaysian medicinal herbs","volume":"36","author":"Salleh","year":"2019","journal-title":"Trop. Biomed."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejphar.2017.12.029","article-title":"Inhibition of dengue viral infection by diasarone-I is associated with 2\u2032O methyltransferase of NS5","volume":"821","author":"Yao","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1021\/acsomega.8b02861","article-title":"Inhibition of Dengue Virus Protease by Eugeniin, Isobiflorin, and Biflorin Isolated from the Flower Buds of Syzygium aromaticum (Cloves)","volume":"4","author":"Saleem","year":"2019","journal-title":"ACS Omega"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Shin, H.J., Kim, M.-H., Lee, J.-Y., Hwang, I., Yoon, G.Y., Kim, H.S., Kwon, Y.-C., Ahn, D.-G., Kim, K.-D., and Kim, B.-T. (2021). Structure-Based Virtual Screening: Identification of a Novel NS2B-NS3 Protease Inhibitor with Potent Antiviral Activity against Zika and Dengue Viruses. Microorganisms, 9.","DOI":"10.3390\/microorganisms9030545"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.antiviral.2018.05.003","article-title":"Identification of Compound-B, a novel anti-dengue virus agent targeting the non-structural protein 4A","volume":"155","author":"Nobori","year":"2018","journal-title":"Antiviral Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1128\/AAC.02462-15","article-title":"Escape mutations in NS4B render dengue virus insensitive to the antiviral activity of the paracetamol metabolite AM404","volume":"60","author":"Overheul","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"eabb2181","DOI":"10.1126\/scitranslmed.abb2181","article-title":"NITD-688, a pan-serotype inhibitor ofthe dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models","volume":"13","author":"Moquin","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2015.01.002","article-title":"Characterization of the activity of 2\u2032-C-methylcytidine against dengue virus replication","volume":"116","author":"Lee","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1021\/acs.jmedchem.5b00327","article-title":"5\u2032-silylated 3\u2032-1,2,3-triazolyl thymidine analogues as inhibitors of West Nile Virus and Dengue virus","volume":"58","author":"Vernekar","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Bullard, K.M., Gullberg, R.C., Soltani, E., Steel, J.J., Geiss, B.J., and Keenan, S.M. (2015). Murine efficacy and pharmacokinetic evaluation of the flaviviral NS5 capping enzyme 2-thioxothiazolidin-4-one inhibitor BG-323. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130083"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"8730","DOI":"10.1128\/JVI.00384-12","article-title":"Identification of a Novel Antiviral Inhibitor of the Flavivirus Guanylyltransferase Enzyme","volume":"86","author":"April","year":"2012","journal-title":"J. Virol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1021\/acsinfecdis.5b00070","article-title":"Identification and Characterization of Novel Broad-Spectrum Inhibitors of the Flavivirus Methyltransferase","volume":"1","author":"Brecher","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/erv.09.139","article-title":"Domain III of the envelope protein as a dengue vaccine target","volume":"9","author":"Guzman","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1021\/cb400612h","article-title":"Allosteric inhibition of the NS2B-NS3 protease from dengue virus","volume":"8","author":"Yildiz","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/AAC.03543-14","article-title":"Novel dengue virus NS2B\/NS3 protease inhibitors","volume":"59","author":"Wu","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.antiviral.2015.03.014","article-title":"The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development","volume":"118","author":"Luo","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1128\/JVI.03453-14","article-title":"Characterization of Dengue Virus NS4A and NS4B Protein Interaction","volume":"89","author":"Zou","year":"2015","journal-title":"J. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/ml500521r","article-title":"Lead optimization of spiropyrazolopyridones: A new and potent class of dengue virus inhibitors","volume":"6","author":"Zou","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"8233","DOI":"10.1128\/JVI.00855-15","article-title":"Discovery of Dengue Virus NS4B Inhibitors","volume":"89","author":"Wang","year":"2015","journal-title":"J. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"104921","DOI":"10.1016\/j.antiviral.2020.104921","article-title":"Interference of dengue replication by blocking the access of 3\u2032 SL RNA to the viral RNA-dependent RNA polymerase","volume":"182","author":"Tunghirun","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1080\/07391102.2019.1666744","article-title":"Evaluating the suitability of RNA intervention mechanism exerted by some flavonoid molecules against dengue virus MTase RNA capping site: A molecular docking, molecular dynamics simulation, and binding free energy study","volume":"38","author":"Manjula","year":"2020","journal-title":"J. Biomol. Struct. Dyn."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/22\/6768\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:28:11Z","timestamp":1760167691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/22\/6768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":90,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["molecules26226768"],"URL":"https:\/\/doi.org\/10.3390\/molecules26226768","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]}}}